Key pathways are VEGF and HIF-α, which are pivotal in promoting angiogenesis and ensuring the tumor’s blood supply, and CTLA-4 and PD-1/PD-L1 pathways, which are central to immune checkpoint regulation and enable tumors to evade immune surveillance by inhibiting T cell activity. The gene discussed is PDCD1; the disease is neoplasm.